Most Indian pharma companies target regulated markets like the US, UK, or Australia. Balaxi uniquely focuses on non-English-speaking frontier markets such as Guatemala, Honduras, El Salvador, Angola, and the Dominican Republic. These countries have high demand for medicines but limited local manufacturing, allowing Balaxi to create a dominant presence. Unlike many exporters that sell bulk drugs or generics to third-party distributors, Balaxi registers its products in each country under its own brand name. This gives it exclusive marketing rights, greater control, and brand equity in those regions.